Clovis Oncology Velat 2024

Mitä Clovis Oncology tekee?

Clovis Oncology Inc. is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. The company is based in Boulder, Colorado and was founded in 2009. They focus on researching and developing innovative therapies for cancer patients. History: Clovis Oncology was founded by Patrick Mahaffy and his team, who previously worked at Pharmion Corporation and sold the biotech company to Celgene. After the sale of Pharmion, Mahaffy and his colleagues wanted to build something new and started Clovis Oncology. Clovis started its activities in 2009 and initially focused on the development of PARP inhibitors, which can be used for the treatment of breast and ovarian cancer. In 2011, the company conducted Phase I studies with its leading product candidate, Rucaparib. Business model: Clovis Oncology has a business model based on the discovery, development, and commercialization of innovative cancer therapies. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a global network of research and development facilities that allows them to focus on the therapy areas where they are best positioned. Through partnerships and licenses, the company also has access to specialized technologies and expertise in cancer research. Divisions: Clovis Oncology is divided into two divisions: 1. Research and development: Clovis operates an intensive research and development program focused on the discovery and development of new cancer therapies. The focus is on developing PARP inhibitors that offer new treatments for breast and ovarian cancer. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Clovis has a strong pipeline of products in various stages of clinical development. 2. Commercialization: Clovis also has an experienced marketing team responsible for the marketing and distribution of Rucaparib. Rucaparib is a PARP inhibitor approved for the treatment of breast and ovarian cancer in the United States and several other countries. Products: The main product of Clovis Oncology is Rucaparib, a PARP inhibitor for the treatment of breast and ovarian cancer. The medication was approved by the US Food and Drug Administration (FDA) in December 2016 for use in patients with advanced ovarian cancer. Clovis also has a pipeline of products in various stages of clinical development. The company collaborates closely with academic institutions and other companies to explore and develop new therapies. Summary: Clovis Oncology is a biopharmaceutical company specialized in the development and commercialization of cancer drugs. They have a focus on developing PARP inhibitors and currently offer Rucaparib for the treatment of breast and ovarian cancer. Clovis has a strong pipeline of products in various stages of clinical development and collaborates closely with academic institutions and other companies to advance cancer research. Clovis Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.